A Phase Ⅰb Study Evaluating Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma is a PHASE1 clinical asset sponsored by Peking Union Medical College Hospital in B-cell Non-Hodgkin Lymphoma. SEO and diligence focus: CD19-directed CAR-T cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.